Foghorn Therapeutics Inc. (FHTX) stock
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.83+0.04 (+2.23%)
Close on Nov 17, 2026Market cap $108.68MP/E –Yield –
Foghorn Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Foghorn Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$72.76M. For fiscal 2025 it was -$86.39M. The highest annual figure on record is -$51.08M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$86.39M | – |
| FY2024 | Dec 31, 2024 | -$102.68M | – |
| FY2023 | Dec 31, 2023 | -$107.91M | – |
| FY2022 | Dec 31, 2022 | -$117.14M | – |
| FY2021 | Dec 31, 2021 | -$100.73M | – |
| FY2020 | Dec 31, 2020 | -$68.53M | – |
| FY2019 | Dec 31, 2019 | -$51.08M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.81M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.57M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.88M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.50M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.10M | – |
| Q1 FY2025 | Mar 31, 2025 | -$22.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.01M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.63M | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.19M | – |
| Q4 FY2023 | Dec 31, 2023 | -$25.46M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.05M | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.32M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$28.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.19M | – |
| Q1 FY2022 | Mar 31, 2022 | -$27.80M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.08M | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.26M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.26M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.13M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.78M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.49M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.54M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.72M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.19M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.10M | – |
See a number that looks wrong?